Overview of the CAPItello-291 Trial

Author(s):

Joyce O’Shaughnessy, MD,Laura Huppert, MD

Panelists discuss the findings of the CAPItello-291 trial, which investigated capivasertib combined with fulvestrant in advanced hormone receptor–positive, HER2-negative breast cancer, leading to its approval in November 2023 and highlighting its potential as a new targeted therapy option in the second-line setting due to the prevalence of PIK3CA, AKT1, and PTEN alterations.

EP: 1.Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

EP: 2.First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

EP: 3.Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

Now Viewing

EP: 4.Overview of the CAPItello-291 Trial

EP: 5.Clinical Experience with Capivasertib

EP: 6.Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy

EP: 7.Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia

EP: 8.Best Practices in Managing Patients on Capivasertib

Video content above is prompted by the following:

Dr Huppert: Please summarize the findings of the CAPItello-291 trial investigating capivasertib plus fulvestrant in the advanced hormone receptor–positive, HER2- negative setting, which led to its approval in November 2023. Turner NEJM 2023
Given the frequency of P13KCA, AKT1, and PTEN alterations, how does capivasertib plus fulvestrant represent a new targeted therapy option in the second-line setting?
Dr Huppert: What patient factors do you consider when initiating patients on capivasertib?